International audienceBackgroundActivation of the TREM-1 pathway is associated with outcome in life threatening COVID-19. Data suggest that modulation of this pathway with nangibotide, a TREM-1 modulator may improve survival in TREM-1 activated patients (identified using the biomarker sTREM-1).MethodsPhase 2 double-blind randomized controlled trial assessing efficacy, safety, and optimum treatment population of nangibotide (1.0 mg/kg/h) compared to placebo. Patients aged 18–75 years were eligible within 7 days of SARS-CoV-2 documentation and within 48 h of the onset of invasive or non-invasive respiratory support because of COVID-19-related ARDS. Patients were included from September 2020 to April 2022, with a pause in recruitment between J...
International audienceOBJECTIVES: Severe COVID-19 is associated with exaggerated complement activati...
Importance: Effective treatments for patients with severe COVID-19 are needed. Objective: To ev...
Introduction Since the start of the SARS-CoV-2 pandemic, several treatment options have been propose...
International audienceSummaryBackgroundActivation of the triggering receptor expressed on myeloid ce...
INTRODUCTION: Septic shock is the subgroup of patients with sepsis, which presents as vasopressor de...
PURPOSE: Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host-pathogens interac...
International audienceBackground: Neuraminidase inhibitors were widely used during the 2009–10 influ...
BACKGROUND: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Contains fulltext : 238020.pdf (Publisher’s version ) (Open Access)Patients with s...
Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence...
Background: No specific antiviral drug has been proven effective for treatment of patients with...
The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise reli...
BACKGROUND: Early intramuscular administration of SARS-CoV-2-neutralising monoclonal antibody combin...
National audienceGiven the current scarcity of curative treatment of COVID-19, the search for an eff...
International audienceOBJECTIVES: Severe COVID-19 is associated with exaggerated complement activati...
Importance: Effective treatments for patients with severe COVID-19 are needed. Objective: To ev...
Introduction Since the start of the SARS-CoV-2 pandemic, several treatment options have been propose...
International audienceSummaryBackgroundActivation of the triggering receptor expressed on myeloid ce...
INTRODUCTION: Septic shock is the subgroup of patients with sepsis, which presents as vasopressor de...
PURPOSE: Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host-pathogens interac...
International audienceBackground: Neuraminidase inhibitors were widely used during the 2009–10 influ...
BACKGROUND: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Contains fulltext : 238020.pdf (Publisher’s version ) (Open Access)Patients with s...
Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, ...
Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence...
Background: No specific antiviral drug has been proven effective for treatment of patients with...
The COVID-19 pandemic has disrupted life throughout the world. Newly developed vaccines promise reli...
BACKGROUND: Early intramuscular administration of SARS-CoV-2-neutralising monoclonal antibody combin...
National audienceGiven the current scarcity of curative treatment of COVID-19, the search for an eff...
International audienceOBJECTIVES: Severe COVID-19 is associated with exaggerated complement activati...
Importance: Effective treatments for patients with severe COVID-19 are needed. Objective: To ev...
Introduction Since the start of the SARS-CoV-2 pandemic, several treatment options have been propose...